银屑病关节炎表型聚类及其与治疗反应的关系:来自银屑病关节炎研究联盟的真实世界纵向队列研究
在银屑病关节炎研究联盟(PARC)多中心研究中,对627例银屑病关节炎(PsA)患者进行混合数据因子分析和主成分层次聚类,识别出3个表型聚类,并评估其转变及对新免疫调节治疗和肿瘤坏死因子抑制剂(TNFi)的反应。聚类3在cDAPSA和PsAID上改善最大,但TNFi起始者中未见差异;聚类随时间保持稳定。
要点
- 识别出3个聚类:轻度PsA伴仅银屑病(47.4%)、重度PsA伴轻度银屑病(34.3%)、重度PsA伴重度银屑病(18.3%)。
- 339例起始或更换治疗者中,聚类3的cDAPSA和PsAID改善最大,但TNFi起始者(n=218)中无差异。
- cDAPSA缓解和PsAID患者可接受症状状态分别达到10%和54%。
核心结论
- 真实世界研究识别出具有不同治疗反应的数据驱动聚类,凸显PsA的广泛异质性及银屑病和肌肉骨骼严重程度对治疗结局的核心作用。
- 这些发现强调需要更好的结局测量工具,尤其是对疾病活动度较低的患者。
研究设计与样本
- 多中心银屑病关节炎研究联盟(PARC)研究,纳入627例PsA患者。
- 采用混合数据因子分析降维并处理共线性,随后进行主成分层次聚类。
- 评估PsA聚类的转变及其对新免疫调节治疗和TNFi的反应。
主要发现
- 627例患者中识别出3个聚类:聚类1(轻度PsA伴仅银屑病)占47.4%,聚类2(重度PsA伴轻度银屑病)占34.3%,聚类3(重度PsA伴重度银屑病)占18.3%。
- 339例起始或更换治疗的患者中(平均随访0.7年,标准差0.8),观察到反应存在显著差异,聚类3在cDAPSA和PsAID上改善最大。
- 起始TNFi的患者(n=218)中未发现聚类间差异。
- cDAPSA缓解和PsAID患者可接受症状状态分别达到10%和54%。
- 尽管治疗改变,聚类随时间保持稳定,但发生了一些转变,尤其是从聚类3向较轻聚类转变。
关键数值与推荐
- 聚类1:轻度PsA伴仅银屑病(PsO),占47.4%。
- 聚类2:重度PsA伴轻度PsO,占34.3%。
- 聚类3:重度PsA伴重度PsO,占18.3%。
- 339例起始或更换治疗者平均随访0.7年(标准差0.8)。
- 起始TNFi者n=218。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify phenotype clusters and their trajectories in psoriatic arthritis (PsA) and examine the association of the clusters with treatment response in a real-world setting. METHODS: In the multicentre PsA Research Consortium (PARC) study, we applied factor analysis of mixed data to reduce dimensionality and collinearity, followed by hierarchical clustering on principal components. We then evaluated the transition of PsA clusters and their response to new immunomodulatory therapy and tumour necrosis factor inhibitor (TNFi). RESULTS: Among 627 patients with PsA, three clusters were identified: mild PsA and psoriasis only (PsO) (Cluster 1, 47.4%), severe PsA and mild PsO (Cluster 2, 34.3%) and severe PsA and severe PsO (Cluster 3, 18.3%). Among 339 patients starting or changing, significant differences in response were observed (mean follow-up of 0.7 years, SD 0.8), with Cluster 3 showing the largest improvements in cDAPSA and PsAID. No differences were found among those starting TNFi (n=218). cDAPSA remission and PsAID patient acceptable symptom state were achieved in 10% and 54%, respectively. Clusters remained stable over time despite treatment changes, though some transitions occurred, notably from Cluster 3 to milder clusters. CONCLUSION: Data-driven clusters with distinct therapy responses identified in this real-world study highlight the extensive heterogeneity in PsA and the central role of psoriasis and musculoskeletal severity in treatment outcomes. Concurrently, these findings underscore the need for better outcome measures, particularly for individuals with lower disease activity.
引用
- Karmacharya P, Crofford LJ, Byrne DW, et al. Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium. Ann Rheum Dis. 2025. PMID: 39919898. doi:10.1136/ard-2024-226150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。